Mabel C. Bush
Research Subjects
Research Interests
Mabel C. Bush has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Avneel S. Hundal
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Banmeet S. Anand
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Bryan D. Lemon
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Che-Leung Law
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Chi-Heng Wu
Harpoon Therapeutics, South San Francisco, California
85 shared publications - Evan C. Callihan
Harpoon Therapeutics, South San Francisco, California
85 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S8 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Pharmacokinetic parameters for HPN328 dosed IV in cynomolgus monkeys.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S8 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Pharmacokinetic parameters for HPN328 dosed IV in cynomolgus monkeys.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S15 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TriTAC mediated cytotoxic activity in vitro and in vivo in the hCD3ε mouse model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S15 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TriTAC mediated cytotoxic activity in vitro and in vivo in the hCD3ε mouse model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Antibodies used for immunophenotyping hCD3ε syngeneic model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Antibodies used for immunophenotyping hCD3ε syngeneic model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values for HPN328 induced expression of TNF⍺ and IFNγ.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values for HPN328 induced expression of TNF⍺ and IFNγ.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S17 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
HPN328 treatment in cynomolgus monkeys leads to transient reduction in circulating T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S17 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
HPN328 treatment in cynomolgus monkeys leads to transient reduction in circulating T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S12 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
IHC staining of NCI-H82 xenograft tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
IHC staining of NCI-H82 xenograft tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values from TDCC assays with anti-DLL3 TriTAC in the C:A:T Configuration (HPN328).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
EC50 Values from TDCC assays with anti-DLL3 TriTAC in the C:A:T Configuration (HPN328).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Stimulation with anti-human CD3 and anti-mouse CD28 beads induces proliferation and activation of T cells from hCD3ε mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
Stimulation with anti-human CD3 and anti-mouse CD28 beads induces proliferation and activation of T cells from hCD3ε mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TDCC co-cultures show no secretion of cytokines in the presence DLL3 negative tumor cell line.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from HPN328, a Trispecific T Cell–Activating Protein Construct Targeting DLL3-Expressing Solid Tumors
TDCC co-cultures show no secretion of cytokines in the presence DLL3 negative tumor cell line.